Table 2.
Operative and treatment characteristics
| Characteristics | N = 227 |
|---|---|
| Number of chemotherapy lines | |
| 1 | 207 (91.2) |
| >1 | 20 (8.8) |
| Neoadjuvant chemotherapy regimen | |
| Monotherapy (capecitabine/5-fluorouracil) | 2 (0.9) |
| Doublet (FOLFIRI/FOLFOX) | 90 (39.6) |
| Triplet (FOLFIRI+biologic agent/FOLFOX+biologic agent/FOLFIRINOX) | 125 (55.1) |
| Quadruplet (FOLFIRINOX+biologic agent) | 10 (4.4) |
| Neoadjuvant biologic agent, | |
| None | 96 (42.3) |
| EGFR antibody (cetuximab/panitumumab) | 39 (17.2) |
| VEGF antibody (bevacizumab) | 57 (25.1) |
| Mean number of neoadjuvant chemotherapy cycles (SD) | 6.02 ± 3.01 |
| Mean Peritoneal Cancer Index (SD) | 8.79 ± 7.31 |
| Completeness of cytoreductive surgery | |
| CC0 | 215 (95.1) |
| CC1 | 11 (4.9) |
| Missing data | 1 |
| HIPEC | |
| No | 197 (86.8) |
| Yes | 30 (13.2) |
| Primary tumor differentiation | |
| Good | 35 (15.4) |
| Moderate | 92 (40.5) |
| Low | 25 (11) |
| Missing data | 6 |
| KRAS status | |
| Wild-type | 110 (60.4) |
| Mutated | 72 (39.6) |
| Missing data | 45 |
| Postoperative morbidity at 90 days (grade III–IV) | |
| No | 141 (62.1) |
| Yes | 86 (37.9) |
| Mean number of days of hospitalization (SD) | 17.43 ± 9.65 |
| Adjuvant chemotherapy protocol | |
| Monotherapy (capecitabine/5-fluorouracil) | 15 (6.8) |
| Doublet (FOLFIRI/FOLFOX) | 152 (69.1) |
| Triplet (FOLFIRI+biologic agent/FOLFOX+biologic agent/FOLFIRINOX) | 46 (20.9) |
| Quadruplet (FOLFIRINOX+biologic agent) | 7 (3.1) |
| Missing data | 7 |
| Adjuvant biological agent | |
| None | 173 (76.2) |
| EGFR antibody | 15 (6.6) |
| VEGF antibody | 35 (15.4) |
| Unknown | 4 |
| Mean number of adjuvant chemotherapy cycles (SD) | 5.96 ± 2.06 |
| Mean number of preoperative days without systemic chemotherapy (SD) | 37.63 ± 17.53 |
| Mean number of postoperative days without systemic chemotherapy (SD) | 63.16 ± 19.19 |
| Mean number of total perioperative days without systemic chemotherapy (SD) | 100.79 ± 26.02 |
| Total number of perioperative chemotherapy cycles (SD) | 11.98 ± 2.9 |
Data are expressed as n (%) unless otherwise specified
SD standard deviation, EGFR epidermal growth factor receptor, VEGF vascular endothelial growth factor, HIPEC hyperthermic intraperitoneal chemotherapy